Related Experiment Video
Updated: May 18, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.
Eliabe S Abreu1, Mazen Noureddin2, Hirokazu Takahashi3
1Division of Gastroenterology & Hepatology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.
Clinics in Liver Disease
|May 16, 2026
Summary
Metabolic dysfunction-associated steatohepatitis (MASH) treatment is evolving beyond lifestyle changes. New FDA-approved therapies like resmetirom and semaglutide offer options for patients with significant liver fibrosis, paving the way for personalized MASH care.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease, historically managed with lifestyle modifications.
- Lifestyle changes remain crucial but are insufficient for many patients with advanced MASH.
- Significant hepatic fibrosis (F2-F3) characterizes patients who may benefit from pharmacologic interventions.
Purpose of the Study:
- To review current FDA-approved and emerging therapies for MASH treatment.
- To discuss the role of novel agents in managing MASH and MASH-related cirrhosis.
- To highlight the potential for personalized treatment approaches in MASH.
Main Methods:
- Review of current literature on MASH treatment guidelines and clinical trials.
- Analysis of FDA-approved medications for MASH with significant fibrosis.
- Exploration of emerging therapeutic strategies and future directions in MASH management.
Main Results:
- Lifestyle modification is foundational but not always sufficient for MASH treatment.
- Resmetirom and semaglutide are FDA-approved for MASH patients with F2-F3 fibrosis.
- Future therapies promise personalized treatment strategies for MASH.
Conclusions:
- The treatment landscape for MASH is expanding with new pharmacologic options.
- Targeted therapies offer new hope for patients with MASH and significant liver fibrosis.
- Personalized medicine approaches will likely shape future MASH management.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:24Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...